Lymphoma Trial, Recruiting NCT07003100 Sponsor: City of Hope Medical Center Condition: Lymphoma
Back to Lymphoma

Lymphoma Trial, Recruiting

NCT07003100
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older who have been diagnosed with Mycosis Fungoides (a type of skin lymphoma) at stage IB, IIA, IIB, III, or IV, or with Sézary Syndrome (a related blood cancer), where the condition has come back or stopped responding to previous treatment
  • People whose treating doctor has chosen to start them on a medication called mogamulizumab as a single treatment (not yet started)
  • People who are willing to have a tissue sample (biopsy) taken from the skin before and possibly during treatment, if the doctor thinks it is needed
  • People who are willing to provide a blood sample at the start of the trial and possibly again if a specific skin rash related to mogamulizumab develops
  • People who have read and signed a form agreeing to take part in the trial

Who may not be able to join:

  • People who are currently receiving other treatments — either whole-body (systemic) or skin-directed — for their skin lymphoma, with the exception of steroid creams or ointments applied to the skin
  • People who have previously been treated with mogamulizumab at any point

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 6 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
6 December 2024
Est. completion
19 October 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Binary incidence of mogamulizumab-associated rash (MAR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov